Genentech, part of Roche, agreed to pay DualityBio $45 million upfront to develop antibody-drug conjugates built around the company’s DUPAC payload platform, with milestone potential exceeding $1 billion across programs. DualityBio will lead discovery and early global clinical development through Phase Ia, while Genentech will take over for later development and commercialization. The pact targets ADC resistance—particularly as topoisomerase inhibitor-based payloads expand across earlier lines. DualityBio positions DUPAC payloads as next-generation options designed to overcome resistance and support broader solid-tumor biology coverage through linker stability and targeted release.